CSL Plasma, Grifols S.A. and Octapharma AG are Dominating the Global Plasma Fractionation Market in 2021

Global Plasma Fractionation Market is expected to grow with the CAGR of 6.5% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-plasma-fractionational-market

Global plasma fractionation market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in global rehabilitation therapy services market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In May 2021, CSL Pharma and The Colorado Cross-Disability Coalition formed an agreement to expand opportunities for people with disabilities to donate plasma. This will help the company enhance its ability to provide plasma to treat individuals suffering from serious diseases.

CSL Plasma is the dominating player in global plasma fractionation market. The other key players existing in the market are Grifols S.A., Octapharma AG, Kendrion S.p.A, Takeda Pharmaceutical Company Limited., Baxter, ADMA Biologics Inc., Bharat Serums and Vaccines Limited (BSV), Bio Products laboratory Ltd., Biotest AG, Boccard, Centurion, China Biologic Products Holdings, Inc., Green Cross Corp, Intas Pharmaceuticals Ltd, Japan Blood Products Organization, Kabafusion, LFB S.A., Merck KGaA, Novasep, Pall Corporation, Sanquin, Shanghai RAAS, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and SK plasma among others.

Plasma Fractionation MarketCSL Plasma

CSL plasma is headquartered in Florida, U.S. and was founded in 1998. The company is focused on collecting blood plasma across the U.S. through about 60 donation centres in about 25 states. The company has wide product categories such as immunology, haematology, respiratory and albumin, in which immunology, haematology and albumin is the market focused category. The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In April 2021, CSL Pharma and BOCA RATON, Terumo Blood and Cell Technologies announced a collaboration to provide a new plasma collection platform at CSL Plasma U.S. collection centers. This will help the company to serve patients a more significant platform that requires plasma for therapeutic purposes.

The company has wide presence across Europe and Americas. The company also has various subsidiary companies such as CSL Plasma (US), CSL Behring UK Limited (UK), and CSL Behring KK among others.

Grifols S.A.  

Grifols S.A. was founded in 1940. The company’s headquarter is in Barcelona, Spain. The company is focused on engaging in the production of plasma derivatives. The company has wide product categories such as coagulation, immunology and neurology, intensive care, pulmonology in which coagulation and intensive care are the market focused product. The company is attaining lucrative growth through several strategic initiatives.

  • In May 2021, Grifols, S.A. announced a collaboration with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR. This will help the company to expand in basic and applied research related to diseases such as Alzheimer’s, among others.

The company has presence across Asia-Pacific, Europe, Americas and Middle East and Africa. The company also has various subsidiary companies such as Biomat USA, Inc. (U.S.), GigaGen, Inc. (U.S.), Grifols Worldwide Operations Ltd. (Ireland) and others.

Octapharma AG

Sutter Health is headquartered in Lachen, Switzerland and was founded in 1982. The company is focused on development, manufacture and sale of human proteins derived from human plasma and human cell lines for use as pharmaceuticals and medical treatments. The company has various product categories such as critical care, haematology, immunotherapy, in which critical care, haematology, immunotherapy is the market focused product. The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In October 2020, Octapharma AG announced that the U.S. Food and Drug Administration (FDA) had approved an updated Prescribing Information (PI) for NUWIQ, Octapharma’s human cell line-derived recombinant factor VIII (FVIII). This will help the company to expand its product line for hereditary bleeding disorders.

The company has presence across Americas, Europe, Asia-Pacific, and Middle East and Africa. The company has various subsidiaries such as Octapharma Ltd (U.K.), Life Therapeutics, Inc. (Israel), Octapharma Nordic AB (Finland) and others.